Apply Now
Dr. Ghaneya Mesaad Alkhadairi
Senior Research Associate
Educational Qualifications
PhD in Biological and Biomedical Sciences
Master in Biological and Biomedical Sciences
Entity
Qatar Biomedical Research Institute
Biography
Ghaneya graduated from Qatar University with a Bachelor of Science in Biomedical Sciences in 2006. She received a Qatar Research Leadership Program (QRLP) scholarship from the Qatar National Research Fund (QNRF) in 2016 to pursue her postgraduate education. She holds a Master's and PhD in Biological and Biomedical Sciences from Hamad Bin Khalifa University. Her PhD project focused on exploring the role of cancer testis antigen PRAME in the oncogenesis and tumor progression of breast cancer. She joined Dr. Lawrence Stanton’s team in 2021 as a Senior Research Associate and she is involved in various projects exploring the molecular mechanisms and pathways underlying neurodevelopmental disorders, including Autism Spectrum Disorder (ASD).
PhD in Biological and Biomedical Sciences
College of Health and Life Sciences; Hamad Bin Khalifa University-Qatar Foundation; Doha-Qatar.
2021
Master in Biological and Biomedical Sciences
College of Health and Life Sciences; Hamad Bin Khalifa University-Qatar Foundation; Doha-Qatar.
2017
Bachelor of Science in Biomedical Sciences
Department of Health Sciences-College of Arts and Sciences; Qatar University; Doha-Qatar.
2006
- Patient-derived induced pluripotent cells (iPSCs) and embryonic stem cells (ESCs) models for Studying Autism Spectrum Disorder.
- CRISPR-Cas9 mediated genome editing and high throughput sequencing approaches.
- Identification of genes and the molecular mechanisms underlying neurodevelopmental disorders
- including autism.
Senior Research Associate
Neurological Disorders Research Center; Qatar Biomedical Research Institute-Research Development Center; HBKU.
2021 - Present
Graduate Scholar - Research Associate
Qatar Foundation Research and Development
2016 - 2021
Senior Microbiology Technologist
Department of Laboratory Medicine and Pathology; Hamad Medical Corporation.
2012 - 2016
Medical Microbiology Technologist
Department of Laboratory Medicine and Pathology; Hamad Medical Corporation.
2007 - 2012
PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer. J Transl Med 17 (2019): 1–14.
Cancertestisantigensandimmunotherapy:Where do we stand in the targeting of PRAME? Cancers (Basel)11 (2019): 1–14.
Cancer testis antigen PRAME: an-anti cancer target with immunomodulatory potential. JCMM (2021).
Immune checkpoint inhibitors in triple negative breast cancer treatment: promising future prospects. Front. Oncol. 10 (2021).
NY-ESO-1 based immunotherapy of cancer: Current perspectives. Front. Immunol. 9 (2018).
- 2020; Poster Prize; HMC Virtual Immuno-Oncology Conference; Doha-Qatar.
- 2006; Gold Medal - Educational Excellence Award for Outstanding University Graduate; Doha- Qatar.
- 2001; Educational Excellence - High School; Her Highness Sheikha Moza bint Nasser Al-Missned; Doha-Qatar.